Board Member
ProMIS Neurosciences Inc. (PMN)Equibles does not estimate personal net worth.
Get an email with a short summary when ProMIS Neurosciences Inc. publishes a filing, an earnings call transcript or a press release.
Get PMN alertsNeil Warma is recorded as CEO at ProMIS Neurosciences Inc. (PMN) since August 1, 2024 and Board Member at ProMIS Neurosciences Inc. (PMN). The newest filing on record that lists Neil Warma as Board Member at ProMIS Neurosciences Inc. (PMN) is dated June 1, 2023. ProMIS Neurosciences Inc. reported in an 8-K filed October 10, 2024 that Neil Warma was appointed President and Chief Executive Officer, effective August 1, 2024. ProMIS Neurosciences Inc. reported in an 8-K filed January 3, 2024 that Neil Warma was appointed President and interim Chief Executive Officer and principal executive officer, effective December 30, 2023. Neil Warma has spoken on 2 earnings calls and 3 other investor events across 1 company, most recently for ProMIS Neurosciences Inc. on November 12, 2026. ProMIS Neurosciences Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at ProMIS Neurosciences Inc. includes Gail Farfel (CEO), Gail M. Farfel (CEO), Gail M. Farfel, PhD (CEO) and 7 others.
“On October 8, 2024, ProMIS Neurosciences Inc. (the "Company") appointed Neil Warma as the President and Chief Executive Officer ("CEO") of the Company, effective August 1, 2024.”
“Effective December 30, 2023, the Board appointed Neil Warma as President and interim Chief Executive Officer and principal executive officer of the Company (the "Appointment").”
“PROMIS is entering probably the most important period in its history. Our Phase 1B study, PRECISE-AD, in Alzheimer's disease, is nearing completion. All patient visits are expected to conclude.”
“And thanks for you attending in the audience as well. I'll excuse my voice at the outset in case I need to break for a sip of tea or water, but thanks very much.”
“I'm excited to be here with Larry Alsteele, our Chief Medical Officer, is in the audience with us as well. It's been a fascinating year for Promise. Our focus has been very much on executing and enrolling and dosing patients in our Phase 1B clinical study in Alzheimer's disease.”
“But yeah, thanks everybody for joining for the next few minutes. Neil Warma, CEO of Promise Neurosciences, and anybody who's sitting in the last presentation, this will be a little bit of a shift from data centers.”
“Welcome to all those who are joining us today to discuss Promise Neurosciences results for the second quarter of 2026 and also to review the recent progress across our pipeline.”
2024-08-01–present
Start not stated–present
Last confirmed June 1, 2023
Biotechnology · Healthcare
Board Member, CEO
2024-08-01–present
